Abstract
Qucheng Huang, YuanYuan Zuo, Yining Xie, Zhenye Liu, Leiyi Wang, Hewei Xu
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Parkinson's disease
10.1016/s0140-6736(21)00218-x · 2021
Advances in diagnosis, classification, and management of pain in Parkinson's disease
10.1016/s1474-4422(25)00033-x · 2025
Pathogenesis of Parkinson's Disease
10.1016/j.ncl.2024.12.003 · 2025
Exercise and gait/movement analyses in treatment and diagnosis of Parkinson's Disease
10.1016/j.arr.2023.102147 · 2024
Nanomedicine in the Face of Parkinson's Disease: From Drug Delivery Systems to Nanozymes
10.3390/cells11213445 · 2022
Nanomedicine for Neurodegenerative Disorders: Focus on Alzheimer's and Parkinson's Diseases
10.3390/ijms22169082 · 2021
Blood-brain barrier alterations and their impact on Parkinson's disease pathogenesis and therapy
10.1186/s40035-024-00430-z · 2024
Blood-brain barrier biomarkers
10.1016/bs.acc.2024.04.004 · 2024
Blood-Brain Barrier (BBB) Dysfunction in CNS Diseases: Paying Attention to Pericytes
10.1111/cns.70422 · 2025
An Engineered Bionic Nanoparticle Sponge as a Cytokine Trap and Reactive Oxygen Species Scavenger to Relieve Disc Degeneration and Discogenic Pain
10.1021/acsnano.3c08097 · 2024
Targeted delivery of berberine using bionic nanomaterials for Atherosclerosis therapy
10.1016/j.biopha.2024.117135 · 2024
Targeted ROS Scavenging for Disease Therapies Using Nanomaterials
10.1002/adma.202504435 · 2025
Biomimetic Nanoparticles Enhance Recovery of Movement Disorders in Parkinson's Disease by Improving Microglial Mitochondrial Homeostasis and Suppressing Neuroinflammation
10.1021/acsami.4c22181 · 2025
Platelet-Membrane-Coated Polydopamine Nanoparticles for Neuroprotection by Reducing Oxidative Stress and Repairing Damaged Vessels in Intracerebral Hemorrhage
10.1002/adhm.202300797 · 2023
Lipid nanoparticle-mediated drug delivery to the brain
10.1016/j.addr.2023.114861 · 2023
Efficient Delivery of Lomitapide using Hybrid Membrane-Coated Tetrahedral DNA Nanostructures for Glioblastoma Therapy
10.1002/adma.202311760 · 2024
Recent Advances in Inorganic Chiral Nanomaterials
10.1002/adma.202005506 · 2021
Nano-fiber/net artificial bionic dura mater promotes neural stem cell differentiating by time sequence external-oral administration to repair spinal cord injury
10.7150/thno.102584 · 2025
Design and synthesis of bioinspired nanomaterials for biomedical application
10.1002/wnan.1914 · 2024
Bioinspired soft nanovesicles for site-selective cancer imaging and targeted therapies
10.1002/wnan.1792 · 2022
Nano-Engineering Strategies for Tumor-Specific Therapy
10.1002/cmdc.202300647 · 2024
Advances in Drug Delivery Systems Based on Red Blood Cells and Their Membrane-Derived Nanoparticles
10.1021/acsnano.2c11965 · 2023
Hierarchically structured bioinspired nanocomposites
10.1038/s41563-022-01384-1 · 2023
Bioinspired Screening of Anti-Adhesion Peptides against Blood Proteins for Intravenous Delivery of Nanomaterials
10.1021/acs.nanolett.2c02243 · 2022
Antimicrobial and anti-biofilm activities of bio-inspired nanomaterials for wound healing applications
10.1016/j.drudis.2023.103673 · 2023
Neuromorphic Floating-Gate Memory Based on 2D Materials
10.34133/cbsystems.0256 · 2025
Platelets and diseases: signal transduction and advances in targeted therapy
10.1038/s41392-025-02198-8 · 2025
Platelets: A new therapeutic target for neurological diseases
10.1016/j.arr.2025.102874 · 2025
Platelet and Megakaryocyte Roles in Innate and Adaptive Immunity
10.1161/circresaha.121.319821 · 2022
Beyond Hemostasis: Platelet Innate Immune Interactions and Thromboinflammation
10.3390/ijms23073868 · 2022
Cell membrane-camouflaged nanomedicines for enhanced thrombolysis and blood-brain barrier penetration in ischemic stroke therapy
10.1016/j.ijpx.2025.100404 · 2025
Recent advances of engineering cell membranes for nanomedicine delivery across the blood-brain barrier
10.1186/s12951-025-03572-y · 2025
Blood-Brain Barrier-Penetrating and Lesion-Targeting Nanoplatforms Inspired by the Pathophysiological Features for Synergistic Ischemic Stroke Therapy
10.1002/adma.202312897 · 2024
Characterization and Chromatographic Isolation of Platelet Extracellular Vesicles from Human Platelet Lysates for Applications in Neuroregenerative Medicine
10.1021/acsbiomaterials.1c01226 · 2021
Neurotrophic Factors in Parkinson's Disease: Clinical Trials, Open Challenges and Nanoparticle-Mediated Delivery to the Brain
10.3389/fncel.2021.682597 · 2021
Multifunctional magnetoliposomes as drug delivery vehicles for the potential treatment of Parkinson's disease
10.3389/fbioe.2023.1181842 · 2023
Microglia rescue neurons from aggregate-induced neuronal dysfunction and death through tunneling nanotubes
10.1016/j.neuron.2024.06.029 · 2024
Characterizing and targeting glioblastoma neuron-tumor networks with retrograde tracing
10.1016/j.cell.2024.11.002 · 2025
Aptamer functionalized cell membrane for brain and nerve cell sensing with high sensitivity and stability
10.1016/j.bios.2023.115149 · 2023
Endogenous cell membrane interactome mapping for the GLP-1 receptor in different cell types
10.1038/s41589-024-01714-1 · 2025
The Yin and Yang of Microglia-Derived Extracellular Vesicles in CNS Injury and Diseases
10.3390/cells13221834 · doi-reference
Clinical Safety and Legal Accountability of Artificial Intelligence in Hematology Diagnostic Laboratories: Risks, Failure Modes, Medicolegal Challenges, and Budgeting for Implementation
10.4103/joah.joah_33_26 · doi-reference
Treatment Options for Motor and Non-Motor Symptoms of Parkinson's Disease
10.3390/biom11040612 · doi-reference
Progress towards therapies for disease modification in Parkinson's disease
10.1016/s1474-4422(21)00061-2 · doi-reference
Utility of Baseline Pathological, Neuroimaging and Clinical Markers for Prognosis in Early Parkinson's Disease
10.1177/08919887251397641 · doi-reference
Evolution of disease modifying therapy clinical trial design and therapeutic endpoints for Parkinson's disease
10.1177/1877718x261420002 · doi-reference
Positron Emission Tomography Imaging in Clinical Trials for Parkinson's Disease: Applications of Metabolic Brain Network Approach
10.1002/mds.30231 · doi-reference
Nanozyme-augmented clinical drug strategy for dopaminergic restoration and oxidative stress mitigation to rescue motor and cognitive deficits in Parkinson's disease
10.1016/j.biomaterials.2026.124391 · doi-reference
Predictive value of cerebrospinal fluid Alzheimer’s disease biomarkers and neuropsychological measures for cognitive and motor outcomes in Parkinson’s disease
10.1093/braincomms/fcag166 · doi-reference
Effect on Dyskinesia of the Early Combination of Amantadine to Levodopa-Therapy in Parkinson's Disease: A Randomized, Placebo-Controlled Study (PREMANDYSK)
10.1002/mds.70120 · doi-reference
Efficacy and Safety of Photobiomodulation Therapy for Motor Symptoms in Parkinson’s Disease: A Systematic Review and Meta-Analysis
10.3390/brainsci16090925 · doi-reference
History of Traumatic Brain Injury Does Not Influence Rate of Progression of Clinical or Pathological Outcomes in Two Early Parkinson's Disease Cohorts
10.1111/ene.70090 · doi-reference
Reprogramming cancer therapeutics through artificial intelligence-guided drug repurposing: Computational innovation, experimental validation, and translational challenges
10.1016/j.ailsci.2026.100168 · doi-reference
Large-scale proteomic analyses of incident Parkinson's disease reveal new pathophysiological insights and potential biomarkers
10.1038/s43587-025-00818-0 · doi-reference
Single-cell transcriptomic and proteomic analysis of Parkinson's disease brains
10.1126/scitranslmed.abo1997 · doi-reference
Monogenic Parkinson's Disease: Genotype, Phenotype, Pathophysiology, and Genetic Testing
10.3390/genes13030471 · doi-reference
Brain microenvironment-remodeling nanomedicine improves cerebral glucose metabolism, mitochondrial activity and synaptic function in a mouse model of Alzheimer's disease
10.1016/j.biomaterials.2025.123142 · doi-reference
Nanomaterial technologies for precision diagnosis and treatment of brain hemorrhage
10.1016/j.biomaterials.2025.123269 · doi-reference
Freestanding nanomaterials for subcellular neuronal interfaces
10.1016/j.isci.2021.103534 · doi-reference
Neurotransmitter systems in the etiology of major neurological disorders: Emerging insights and therapeutic implications
10.1016/j.arr.2023.101994 · doi-reference
AI-enhanced virtual screening approach to hit identification for GluN1/GluN3A NMDA receptor
10.1038/s41401-025-01644-1 · doi-reference
Furan-Derived Lipid Nanoparticles for Transporting mRNA to the Central Nervous System
10.1021/jacs.4c16326 · doi-reference
Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed
10.1186/s40364-022-00373-5 · doi-reference
Brain drug delivery and neurodegenerative diseases: Polymeric PLGA-based nanoparticles as a forefront platform
10.1016/j.arr.2022.101658 · doi-reference
Single-cell RNA sequencing of CSF reveals neuroprotective RAC1(+) NK cells in Parkinson's disease
10.3389/fimmu.2022.992505 · doi-reference
Neurodegeneration models in Parkinson's disease: cellular and molecular paths to neuron death
10.1186/s12993-025-00279-w · doi-reference
Abstract 2045: Novel TFRC humanized mouse model for drug delivery to the brain
10.1158/1538-7445.am2024-2045 · doi-reference
Receptor-mediated transcytosis of nanobodies targeting the heparin-binding EGF-like growth factor in human blood-brain barrier models
10.1016/j.jconrel.2025.113852 · doi-reference
The Crucial Role of the Blood-Brain Barrier in Neurodegenerative Diseases: Mechanisms of Disruption and Therapeutic Implications
10.3390/jcm14020386 · doi-reference
Biomimetic nanodelivery system with simultaneous blood-brain barrier-crossing and neuroprotective abilities for anti-parkinsonian therapy
10.1186/s13020-025-01239-2 · doi-reference
The Impact of the Blood-Brain Barrier and Its Dysfunction in Parkinson's Disease: Contributions to Pathogenesis and Progression
10.1021/acsomega.4c06546 · doi-reference
Novel single-domain antibodies targeting a unique transferrin receptor 1 epitope for cross-species delivery of drugs in the central nervous system
10.1016/j.jconrel.2025.114344 · doi-reference
Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset
10.1002/jps.23575 · doi-reference
Mastering Quality: Uniting Risk Assessment With Quality by Design (QbD) Principles for Pharmaceutical Excellence
10.7759/cureus.68215 · doi-reference
MXene-Based Nanomaterials for Bacterial Detection and Sonodynamic Sterilization
10.1002/smll.74682 · doi-reference
Bioinspired Membrane-Based Cancer Vaccines for Immunotherapy: Progress and Perspectives
10.1002/smll.202412679 · doi-reference
Black Phosphorus Nanosheets Protect Neurons by Degrading Aggregative α-syn and Clearing ROS in Parkinson's Disease
10.1002/adma.202404576 · doi-reference
ROS-Drp1-mediated mitochondria fission contributes to hippocampal HT22 cell apoptosis induced by silver nanoparticles
10.1016/j.redox.2023.102739 · doi-reference
Transforming the concept of connectivity: unveiling tunneling nanotube biology and their roles in brain development and neurodegeneration
10.1152/physrev.00023.2024 · doi-reference
Brain Targeting Nanomedicines: Pitfalls and Promise
10.2147/ijn.s454553 · doi-reference